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Abstract Biocharacterization of circulating tumor cells
(CTCs) in the peripheral blood of advanced breast cancer
(ABC) patients may represent a real-time tumor biopsy. We
assessed HER2 status on CTCs from blood samples of ABC
patients. CTCs were separated and stained using the Cell-
Search System. HER2 status was assessed by immu-
nofluorescence and, when technically feasible, by fluores-
cence in situ hybridization. Blood samples were obtained
from 66 ABC patients. Forty patients had a positive CTC
sample (61%) and of these, 15 (37%) had HER2 ? CTCs.
We found non-concordant results in 32% of cases: 29% (8/
28) of HER2-negative primary tumors had HER2-positive
CTCs and 42% (5/12) of HER2-positive primary tumors
had HER2-negative CTCs (k = 0.278). Our study suggests
that a subset of patients with HER2-negative primary
tumors develops HER2-positive CTCs during disease
progression.
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Introduction
Metastatic disease, the most common cause of death in
cancer patients, is a multistep process during which tumor
cells disseminate from the primary tumor site and establish
secondary tumors in remote sites [1]. The detection and
biocharacterization of circulating tumor cells in cancer
patients may provide relevant information on the progres-
sion of metastatic events and may have important impli-
cations for disease prognosis and treatment choices [2].
Circulating tumor cells (CTCs) can be detected from the
peripheral blood of early or metastatic breast cancer
patients [3–5]. A semiautomated system, the CellSearchTM
system (Immunicon Corp., Huntington valley, PA, USA),
has been developed for CTCs isolation using an EpCAM
antibody-based immunomagnetic enrichment and an auto-
mated staining methodology [6]. This assay has been
shown to have high specificity and reproducibility [7]. In
landmark papers, Cristofanilli et al. have used this assay for
CTCs isolation from blood samples of metastatic breast
cancer patients. A major finding of these studies, carried
out according to the REMARK Criteria [8], was that CTCs
quantification, performed before and during treatment,
predicted a response to medical therapies as early as
3–4 weeks after initiation of treatment. In addition, CTCs
baseline quantification was a predictor of overall survival
[9, 10].
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Current use of targeted therapies is based on the concept
that metastatic cells are linear descendants of primary
tumor cells with the same biologic features as the primary
tumor. However, a hallmark of breast cancer is its genetic
instability [11]. CTCs may express contrasting biological
features to the corresponding primary tumor cells. Hence,
CTCs biocharacterization may lead to identification of
specific targets and subsequently direct therapy in
advanced breast cancer patients.
The HER2 gene encodes for a 185-kDa tyrosine kinase
glycoprotein [12]. Trastuzumab, a humanized monoclonal
antibody directed against the extracellular domain of the
HER2 protein, has significantly improved the clinical
outcome of HER2-positive disease [13–15]. Several studies
have compared HER2 status between primary tumors and
matched metastatic site samples [16–19]. All of these
studies have suggested an acceptable level of concordance
between HER2 status of the primary and the metastatic site
samples (concordance rate: 80–94%) [16–19]. Notably, in
these studies, most of the metastatic site samples were
drawn at the time of first relapse. In this context, it is
impossible to account for selective pressure on tumor
clones progression played by different lines of treatment
for metastatic disease [16–19].
In an exploratory study, Meng et al. [20] reported on
nine of 24 advanced breast cancer patients, whose primary
tumor was HER2 negative by FISH, carrying HER2 gene
amplified CTCs. Interestingly, in this study, patients had
advanced disease previously treated with multiple lines of
systemic therapy. These preliminary results support the
hypothesis that in approximately 30% of advanced breast
cancer patients, pretreated with multiple lines of systemic
therapies, a shift in HER2 status might occur when a pri-
mary tumor sample is compared to circulating tumor cells
isolated from the same patient.
Accordingly, we decided to prospectively evaluate the
level of concordance in HER2 status between primary
tumor samples and their corresponding circulating tumor
cells. We collected CTCs from two different series of
breast cancer patients, the first with HER2-negative and the
second with HER2-positive primary tumors. The results of
this study are reported in the present manuscript.
Materials and methods
Study population
Patients with locally advanced or metastatic breast cancer,
with known HER2 status of their primary tumor, were
eligible for this study. All patients were informed about the
experimental design of the study and gave written informed
consent. The study was previously approved by the local
ethical board. Other eligibility criteria were ECOG per-
formance status 0–3, previous systemic treatment(s) for
early or advanced disease were allowed, an inter-
val [ 7 days between last day of systemic treatment and
day of blood sample withdrawal for CTCs evaluation
(http://immunicon.com/CellSearch/CellSearch HCP.aspx).
A previous diagnosis of secondary malignancy was an
exclusion criterion.
A twenty milliliter sample of peripheral blood was
withdrawn at the time of study entry and collected in a
CellsaveTM tube (Immunicon, Huntingdon Valley, PA) that
contains a specific cell preservative. Under these conditions
the sample was stable at room temperature for 72 h. All
samples were processed within 72 h from the withdrawal
time (http://immunicon.com/CellSearch/CellSearch HCP.
aspx).
Ten milliliter of blood was used for CTCs enumeration
and HER2 evaluation by immunofluorescence (IF). The
remaining 10 ml was used for CTCs immunomagnetic
enrichment. Morphological and molecular CTC character-
ization was carried out on the enriched samples.
From the primary tumor samples, histological type,
nodal status, estrogen receptor (ER), progesterone receptor
(PgR), Ki-67, and HER2 status were retrieved from the
pathology report. All of these biomarkers were evaluated
by immunohistochemistry (IHC). The primary tumor was
defined as HER2? if IHC 3? (Pathway HER2-clone
CB11- by Ventana Medical System, Inc., Tucson, Arizona–
USA) or if IHC 2? with evidence of gene amplification by
fluorescence in situ hybridization (FISH) (ratio HER2/CEP
17 [ 2.2) or chromogenic in situ hybridization (CISH)
(HER2 copy number [ 6) [21]. Both FISH and CISH were
performed according to standard procedures (PathVysion
kit for FISH by Abbott Laboratories, Downers Grove, IL-
USA; Spot Light Kit for CISH by Zymed Laboratories,
Inc., San Francisco, CA–dUSA).
CTCs immunomagnetic isolation and HER2
immunofluorescent staining
The methodology for automated CTCs immunomagnetic
isolation and for HER2 immunofluorescent staining has
been described elsewhere [6–11]. Technical details of the
CellSearch and CellSpotter systems pertaining to accu-
racy, precision, linearity, and reproducibility have previ-
ously been reported [6, 7].
Briefly, ferro fluid particles conjugated to anti-EpCAM
antibodies are used for isolation of EpCAM-positive cells
using a magnetic field without centrifugation. Thereafter, the
supernatant, containing unbound cells, is removed and the
enriched sample is processed for fluorescent staining:
nucleic acids are stained with 4, 6-diamidino-2-phenylindole
(DAPI); epithelial cells are stained with anti-cytokeratin
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(CK)-phycoerythrin, and leukocytes are stained with an
allophycocyanin-conjugated anti-CD45 antibody. At this
point, the CellSearchTM HER2 Tumor Phenotyping Reagent
(Immunicon) is added to identify HER2 overexpressing
CTCs.
Stained cells are analyzed on Cell Track Analyzer IITM
(Immunicon), a fluorescence microscope that scans the
reaction cartridge. Cells with a size of at least 4 lm pre-
senting the composite CK?/DAPI?/CD45-/HER-2?
phenotype are classified as HER2-positive CTCs.
In this study, a case was defined as positive for CTCs
when C 2 cell/7.5 ml were isolated [6]. A CTCs-positive
case was defined as HER2-positive when at least 50% of
CTCs were HER2 positive by IF. The arbitrary selected
50% cut-off could potentially identify true HER2-positive
cases on CTCs.
Quality control was maintained via the CellSearchTM
Circulating Tumor Cell Control Kit used to check reagents,
instruments, and operator technique. Moreover, to test the
reliability of the HER2 Tumor Phenotyping Reagent (Im-
municon), blood samples from healthy donors were
spiked with HER2-positive tumor cells (SBRK3 cell line).
Slide preparation for CTC morphological
and molecular analysis
Ten milliliter of blood was used for standard cytology and
molecular analysis. The CellSearch Profile kit (Immuni-
con) was used for automated immunomagnetic isolation
of cells of interest without the staining procedures. The cell
suspension obtained was subsequently cytocentrifugated
and the slide was fixed in Carnoy’s fixative (3:1 methanol:
glacial acetic acid) for 10 min. Papanicolaou staining was
done by standard protocol, and stained cells were examined
by a cytopathologist.
The PathVysion HER2/neu probe kit (Abbott labora-
tories) was used for the FISH analysis applied on a stained
or white slide. Cases were interpreted as amplified when
the ratio of HER2/CEP17 signals was greater than 2.2 [21].
Statistical analysis
Data are presented in tables of frequencies (see Tables 3 and
4). To assess the diagnostic performance of IF for HER2
status, we calculated sensitivity, specificity, and likelihood
ratios, taking the FISH method as the gold standard. Crude
percentage of correct classification and Cohen’s Kappa as
chance-adjusted index of agreement are reported. Inference
on Kappa values is done using standard error under the
alternative hypothesis following Fleiss et al. [22].
To assess agreement on HER2 status between primary
tumor and CTCs, we calculated Cohen’s Kappa and 95%
confidence intervals as mentioned earlier.
Considering that HER2 status on CTCs was evaluated
by IF (i.e., a nonstandardized method), we also calculated
corrected Kappa values taking into account a non-differ-
ential misclassification [23].
Results
CTCs count and cytopathology examination
Between June 2006 and December 2007, 66 patients with
locally advanced (14 patients) or metastatic (52 patients)
breast cancer were considered potentially eligible for the
study. Of the metastatic patients, the vast majority had
progressive disease at the time of study entry.
Among the 66 patients, 40 (61%) were CTCs positive. The
median and the corrected mean of CTCs number were 5 and 85
cells/7.5 ml of blood, respectively (range: 0–60.000). Thirty-
three patients (50%) had at least 5 cells/7.5 ml of blood.
Clinical and biological characteristics of the study
population by CTCs count are shown in Table 1.
Table 2 reports main clinical characteristics of meta-
static breast cancer patients by CTCs count. No clinically
relevant correlations were found.
Twenty-nine CTCs-positive cases were characterized
morphologically by Papanicolaou staining. It was observed
that CTCs differ from cells of the corresponding primary
tumor tissue. In our study, two cell types were observed: the
most common was characterized by small, rounded cells
with a high nucleus/cytoplasmic ratio, either isolated (sim-
ilar to blood cells) or arranged in clusters; the less common
was characterized by larger and sometimes elongated cells
(Fig. 1a–b).
HER2 protein expression and gene
amplification on CTCs
Among the 40 CTCs-positive patients, 25 (63%) were
classified as HER2 negative and 15 (37%) as HER2 posi-
tive by IF analysis (Fig. 1c–d). The mean percentage of
immunofluorescence stained cells was 3 (range: 0–27%) in
the HER2-negative group and 92.5 (range: 50–100%) in
the HER2-positive group.
Thirty-four CTCs-positive cases were evaluated for HER2
gene amplification by FISH. Of these, nine were non-inter-
pretable due to technical issues, five were HER2–amplified,
and twenty were HER2-non-amplified (Fig. 1e–f).
Table 3 summarizes the concordance of HER2 status on
CTCs between IF and FISH. Taking FISH as the gold
standard to define the HER2 status, IF had a sensitivity and
a specificity of 80 and 95%, respectively, and a likelihood
ratio of a positive and negative test equal to 16 and 0.21,
respectively.
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Considering that CTCs were defined as HER2 positive
by IF if C 50% of cells had HER2 staining, we found that
the two techniques had a 92% agreement rate, k = 0.75,
P = 0.033 (95% CI: 0.422–1.000).
HER2 protein expression on CTCs and corresponding
primary tumors
Table 4 summarizes the results of the HER2 status com-
parison between CTCs, evaluated by IF, and corresponding
primary tumor, evaluated by IHC and in situ hybridization.
In our series, we found 13 discordant cases (32%).
Among the HER2-positive primary tumors, 42% (5/12)
developed HER2-negative CTCs. These five patients had
previously been treated with several lines of therapy and
three of them had received trastuzumab before CTCs
analysis. In three of the five HER2-negative cases on
CTCs, FISH evaluation on CTCs was technically feasible
confirming the HER2-negative status.
Among the HER2-negative primary tumors, 29% (8/28)
developed HER2-positive CTCs. In two of the eight cases,
FISH on CTCs was feasible and confirmed the HER2
positivity.
In our series, a weak concordance was found between
HER2 status evaluated on primary tumor and on corre-
sponding CTCs, k = 0,278 (95% CI: -0.028 to 0.584).
As HER2 status on CTCs was defined by IF (i.e., a
nonstandardized method), we applied a correction for non-
differential misclassification of HER2 status on CTCs
using the IF sensitivity and specificity from Table 3.
According to this analysis, corrected kappa, using integer
values, ranges from 0.309 to 0.375; thus, confirming a
weak concordance.
Table 5 reports main patient characteristics for the 13
cases with HER2 discordant results.
HER2 by FISH was reassessed on the primary tumor for
all discordant cases, and in all, the originally assigned
HER2 status was confirmed.
Discussion
In clinical practice, we tend to assume that the expression
of biological markers of metastatic tumors mirrors the
primary tumor biological profile.
However, tumors are biologically and clinically heter-
ogeneous, and systemic therapies may play a role in
selective tumor clones progression, explaining the preva-
lence of a given tumor clone over the others [24].
In the past, studies have explored the concept of biolog-
ical heterogeneity between the primary tumor and its met-
astatic sites by comparing the expression of a given marker,
most frequently HER2 or hormone receptors [16–19].
All of the reported studies had a retrospective design
and, more importantly, in the vast majority of cases
expression of biomarkers was evaluated on a metastatic site
biopsied at the time of the first disease relapse. Of note,
patients experiencing first relapse had not yet received
Table 1 Patient and primary tumor characteristics by CTC count
Patients’ characteristics by CTC count
CTC C 2 CTC \ 2 Overall
Age (years)
C50 32 (80%) 16 (62%) 48
\50 8 (20%) 10 (38%) 18
Histology
Ductal 31 (71%) 19 (73%) 50
Lobular 6 (15%) 5 (19%) 11
Other 3 (8%) 2 (8%) 5
Nodal status
N? 19 (47%) 18 (69%) 37
N- 11 (28%) 3 (12%) 14
Nx 10 (25%) 5 (19%) 15
ER status
Pos 26 (65%) 22 (85%) 48
Neg 13 (33%) 4 (15%) 17
NA 1 (2%) 0 1
PgR status
Pos 16 (40%) 17 (65%) 33
Neg 23 (58%) 9 (35%) 32
NA 1 (2%) 0 1
HER2
Pos 12 (30%) 5 (19%) 17
Neg 28 (70%) 21 (81%) 49
Overall 40 26 66
CTC circulating tumor cells, NA not available
Table 2 Main clinical characteristics of MBC patients by CTC
count
CTC C 2 CTC \ 2 Total patients
(N = 52)
Number of metastatic sites
C3 19 (53%) 7 (44%) 26
\3 17 (47%) 9 (56%) 26
Type of metastatic sites (visceral/non-visceral)
± 3 (8%) 0 3
; 9 (25%) 7 (44%) 16
?/? 24 (67%) 9 (56%) 33
DFI
[12 months 21 (58%) 13 (81%) 34
B12 months 15 (42%) 3 (19%) 18
?, Presence; -, absence
MBC metastatic breast cancer, DFI disease free interval calculated
from date of breast cancer diagnosis to date of first relapse
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treatment for metastatic disease. In this circumstance, the
potential selective pressure played by systemic therapies on
tumor clone progression cannot occur. In addition, in these
studies, biomarkers expression was most frequently eval-
uated on a single metastatic site, assuming that this site
would be representative of the bulk of metastatic disease.
The use of modern technologies allowing for the isola-
tion of CTCs from the peripheral blood of cancer patients
has enabled the undertaking of studies aiming to biologi-
cally characterize metastatic tumors [25–33]. Theoreti-
cally, CTCs isolation and biocharacterization may become
a real time and minimally invasive biopsy of the metastatic
tumor and could provide the clinician with relevant infor-
mation in terms of prognosis and prediction of treatment
activity.
Fig. 1 Morphological analysis: panel a rounded cells with a high
nucleus/cytoplasmic ratio, arranged in clusters; panel b elongated
cells. Immunofluorescence analysis: panels c and d HER2, CK-PE,
and DAPI windows reproduce a computer-elaborated image of the
membrane, cytoplasm, and nucleus, respectively. Panel c positive
circulating tumor cell (DAPI?/CK-PE?/CD45APC-/HER2?);
panel d HER2-negative circulating tumor cell (DAPI?/CK-PE?/
CD45APC-/HER2-). FISH analysis; panel e HER2-amplified
circulating tumor cells; panel f HER2-non-amplified circulating
tumor cells
Table 3 Concordance of HER2 status between IF and FISH eval-
uated on CTC
IF positive IF negative Total
FISH positive 4 1 5
FISH negative 1 19 20
Total 5 20 25
CTC circulating tumor cells, IF immunofluorescence, FISH fluores-
cence in situ hybridization
Kappa (95% CI): 0.750 (0.422–1.000)
Table 4 HER2 status comparison between primary tumors and
corresponding CTC
Primary tumor CTC
HER2? by IF HER2- by IF Total
HER2? 7 5 12
HER2- 8 20 28
Total 15 25 40
CTC circulating tumor cells, IF immunofluorescence
Kappa (95% CI): 0.278 (-0.028 to 0.584)
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In the present study, we have used an immunomagnetic-
based, semiautomated technology namely CellSearch. In
a clinical setting, CTCs counting by CellSearch has been
shown to have a prognostic value for advanced breast
cancer patients [9, 10]. This suggests that CTCs isolated by
this technology are biologically relevant.
In this study, CTCs were isolated in only 61% of the
study population. In addition, only half of the 66 locally
advanced or metastatic cases reported in the present man-
uscript had at least 5 cells/7.5 ml of peripheral blood. The
limited number of CTCs isolated by CellSearch may be
poor representative of the tumor bulk of any single patient,
and it may generate technical difficulties in evaluating
biomarkers.
Conversely, a technology based on microchips and
interaction between CTCs and anti-EpCAM-coated mi-
croposts has shown to be highly sensitive in detecting
relevant numbers of CTCs from peripheral blood samples
of up to 99% of advanced solid tumor patients, although
the clinical significance of isolated CTCs is still unclear
[33].
In the present study, we have focused our efforts on the
comparison of HER2 status between primary tumor and
corresponding CTCs isolated from advanced breast cancer
patients. HER2 is recognized as a clinically important
treatment target [13–15]. The demonstration that some
HER2-negative primary tumors might develop, during the
course of disease progression, HER2-positive CTCs could
clinically be relevant.
Our results seem to support the concept of HER2 status
shifting between the primary tumor and its corresponding
CTCs. The presented results are in line with previously
reported data (Table 6) [34–39]. Nevertheless, it is
important to emphasize that the present study had as pri-
mary end point the evaluation of the HER2 status shift
between primary tumors and CTCs in view of a clinical
trial testing anti-HER2 treatments in patients with HER2-
negative primary tumors and HER2-positive CTCs. Shift-
ing seems to occur in both directions. In five of twelve
HER2-positive primary tumors, CTCs were defined as
HER2-negative. Interestingly, in these five discordant cases
the HER2/CEP17 copy numbers ratio evaluated on the
primary tumor by FISH was close to the cut-off. In addi-
tion, in the eight cases with HER2-negative primary tumor
and HER2-positive CTCs, the number of isolated CTCs
was \10/7.5 ml of blood in all but one cases.
These considerations suggest that the present results
have to be taken with caution.
A further caveat of the present study is the fact that
HER2 status was evaluated by IF on CTCs and by standard
IHC and in situ hybridization on primary tumors. Never-
theless, it is important to emphasize that in 23 of 25 cases
in which both IF and FISH were technically feasible on
peripheral blood samples drawn at the same time from the
same patient, a concordance between the two techniques in
defining the HER2 status on CTCs was found (Table 3).
This suggests that evaluation of HER2 by IF on CTCs may
be accurate enough.
Table 5 Main patient characteristics of the discordant cases
Patient number HER2 assessment on primary tumor D time HER2 assessment by IF on CTC Previous treatmentsa
Method Result (score) Months #CTC % HER2 ? CTC CT HT
CTC011 FISH NA (0.95) 0 3 67 0 0
CTC012 FISH NA (1.36) 36 5 100 3 2
CTC018 FISH NA (1.17) 52 6 67 1 2
CTC022 FISH NA (1.02) 1 5 100 0 0
CTC023 FISH NA (1.19) 68 2 100 0 2
CTC046 FISH NA (1.01) 45 5 100 1 1
CTC048 FISH NA (0.93) 3 5 100 0 1
CTC064 FISH NA (1.07) 1 21 100 0 0
CTC010m FISH A (2.30) 12 11 27 2 1
CTC049 FISH A (2.34) 21 101 2 1 1
CTC055 FISH A (2.58) 52 18 0 0 1
CTC078 FISH A ([2.2) 96 12 8 4 2
CTC079 FISH A ([2.2) 78 37 3 1 3
CTC circulating tumor cells, # number, CT chemotherapy, HT hormonotherapy, NA non-amplified, A amplified, IF immunofluorescence, FISH
fluorescence in situ hybridization
D time: time interval between date of metastatic disease diagnosis and date of CTC evaluation
a For advanced disease
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The results of this study generate a new question: is the
evaluation of HER2 status on CTCs representative of the
metastatic tumor HER2 status? This critical issue must be
addressed because of its clinical relevance. Only a properly
designed clinical trial can address this question. Meng et al.
[20] reported that three of four heavily pretreated advanced
breast cancer patients with HER2-negative primary tumors
and HER2-positive CTCs had an objective tumor response
to trastuzumab combined with chemotherapy. This report,
although hypothesis-generating, is not strong enough to
promote this strategy in the clinical practice. It was not a
prospectively designed clinical trial and patients received
trastuzumab in combination with chemotherapy.
Based on the results of the presently reported study, our
group has recently initiated a prospectively designed phase
II clinical trial, whose primary aim is the evaluation of
single-agent lapatinib in patients with HER2-negative pri-
mary tumors by standard criteria and HER2-positive CTCs.
Whenever feasible, a biopsy from a metastatic site will be
collected in parallel with CTCs biocharacterization. This
will allow for correlation in HER2 status between a met-
astatic tumor sample and CTCs from the same patient. We
believe that the results of this ongoing trial might prag-
matically address the question raised by the present study
in relation to the clinical significance of HER2 status
determination on CTCs.
In conclusion, the present study shows that in 32% of
patients with advanced breast cancer a shift in HER2 status
between the primary tumor and corresponding CTCs
occurred. The shift was seen to be bidirectional. The next
step is the clinical evaluation of anti-HER2 therapies in
patients with HER2-negative primary tumors and HER2-
positive CTCs. An ongoing Phase II trial is addressing this
clinically relevant question.
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